Streetbeat News

Stock Prices

GRWG

GrowGeneration has revised its FY24 revenue forecast to $190M-$195M, which is below the previous estimate of $203.8M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:56 pm

ORGO

Organogenesis Holdings has provided its revenue guidance for FY24, projecting a range of $445 million to $470 million, compared to the analyst estimate of $455.850 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:55 pm

FARO

Faro Technologies (NASDAQ:FARO) reported Q2 2024 adjusted EPS of $0.18, significantly beating the analyst estimate of $0.01. However, sales of $82.085 million missed the $83.651 million estimate and were down 6.94% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:54 pm

SSIC

Silver Spike Investment (NASDAQ:SSIC) reported Q2 2024 GAAP EPS of $0.21 and sales of $3.081 million, significantly beating the analyst consensus estimate of $1.970 million. This represents a 160.88% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:54 pm

ASMB

Assembly Biosciences (NASDAQ:ASMB) reported Q2 EPS of $(1.98), beating the $(2.23) estimate, and sales of $8.53M, surpassing the $5.96M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:53 pm

CRDF

Cardiff Oncology (NASDAQ:CRDF) reported Q2 2024 GAAP EPS of $(0.26), missing the $(0.25) estimate, but achieved sales of $163.000K, significantly beating the $58.750K estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:52 pm

SEER

Seer Inc. has revised its FY24 revenue guidance to $13M-$15M, which is below the previous estimate of $16.7M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:52 pm

JYNT

Joint (NASDAQ:JYNT) reported Q2 2024 adjusted EPS of $(0.06), missing the $(0.02) estimate by 200%. However, sales of $30.261M beat the $29.397M estimate by 2.94%, showing a 3.26% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:52 pm

BHVN

Biohaven (NYSE:BHVN) reported a Q2 loss of $(3.50) per share, significantly missing the analyst consensus estimate of $(1.77) by 97.74%. This represents a 180% increase in losses compared to $(1.25) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:51 pm

APYX

Apyx Medical has adjusted its FY24 total revenue outlook to a range of $50.6M - $52.1M, up from the previous range of $49.7M - $52.9M. The new estimate is slightly above the consensus estimate of $49.99M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:51 pm